Volume 13 - Supplement, Winter
aumj 2024, 13 - Supplement, Winter: 88-102 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Forghani-Ramandi M, Mozhgani S. Determining the key genes and cellular signaling pathways involved in the pathogenesis and development of aggressive types of adult leukemia/lymphoma derived from T (ATLL) cells. aumj 2024; 13 :88-102
URL: http://aums.abzums.ac.ir/article-1-1789-en.html
URL: http://aums.abzums.ac.ir/article-1-1789-en.html
1- Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
2- Department of Microbiology and Virology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
2- Department of Microbiology and Virology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
Abstract: (974 Views)
Background: Adult T-cell leukemia/lymphoma (ATLL) is a cancer with a very poor prognosis. ATLL has four subgroups, acute, chronic, lymphoma, and smoldering, with very different prognoses. In this study, we tried to better understand the pathogenesis of ATLL and the differences between its subgroups by using gene expression data and bioinformatics methods.
Methods: Genes with altered expression were identified among different types of ATLL. In order to determine the key genes, the network of protein interactions between the resulting genes was constructed. After screening the hub genes based on the network centrality indices, the cell signaling pathways related to them were identified.
Results:Comparing the acute type with the chronic and silent types, the cell signaling pathways involved in regulating the function of the immune system are expressed differently. In comparison of acute and chronic type with healthy people, genes related to malignancy are involved. In comparing the silenced type with healthy individuals, the pathways related to infections are disrupted. In the secondary comparison, it was found that the genes related to cell proliferation and malignancy in the acute form were expressed more and the genes related to the immune system were less expressed in these patients than in the rest of the population.
Conclusion:It seems that manipulations by the virus resulting in immune escape and also in increased proliferation of infected cells have a decisive role in the occurrence of the aggressive type of the disease. Further investigations can lead to the development of new diagnostic methods, determining prognosis and even the detection of targets for gene therapy.
Methods: Genes with altered expression were identified among different types of ATLL. In order to determine the key genes, the network of protein interactions between the resulting genes was constructed. After screening the hub genes based on the network centrality indices, the cell signaling pathways related to them were identified.
Results:Comparing the acute type with the chronic and silent types, the cell signaling pathways involved in regulating the function of the immune system are expressed differently. In comparison of acute and chronic type with healthy people, genes related to malignancy are involved. In comparing the silenced type with healthy individuals, the pathways related to infections are disrupted. In the secondary comparison, it was found that the genes related to cell proliferation and malignancy in the acute form were expressed more and the genes related to the immune system were less expressed in these patients than in the rest of the population.
Conclusion:It seems that manipulations by the virus resulting in immune escape and also in increased proliferation of infected cells have a decisive role in the occurrence of the aggressive type of the disease. Further investigations can lead to the development of new diagnostic methods, determining prognosis and even the detection of targets for gene therapy.
Keywords: Adult T-cell leukemia/lymphoma, Human T-cell lymphotropic virus type 1, bioinformatics, ATLL, HTLV-1
Type of Study: Original |
Subject:
Special
Received: 2023/06/24 | Accepted: 2023/08/26 | Published: 2024/02/28
Received: 2023/06/24 | Accepted: 2023/08/26 | Published: 2024/02/28
References
1. Ishitsuka K, Tamura K. Human T-cell leukaemia virustype I and adult T-cell leukaemia-lymphoma. TheLancet Oncology. 2014;15(11):e517-e526. [DOI:10.1016/S1470-2045(14)70202-5]
2. Yamagishi M, Ishida T, Miyake A, et al. Retroviraldelivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. MicrobesInfect. Apr 2009;11(4):500-8. doi:10.1016/j.micinf.2009.02.003 [DOI:10.1016/j.micinf.2009.02.003]
3. Setoyama M, Katahira Y, Kanzaki T. Clinicopathologicanalysis of 124 cases of adult T‐cell leukemia/lymphoma with cutaneous manifestations: thesmouldering type with skin manifestations hasa poorer prognosis than previously thought. TheJournal of dermatology. 1999;26(12):785-790. [DOI:10.1111/j.1346-8138.1999.tb02093.x]
4. Sakihama S, Karube K. Genetic Alterations in AdultT-Cell Leukemia/Lymphoma: Novel Discoverieswith Clinical and Biological Significance. Cancers(Basel). May 12 2022;14(10)doi:10.3390/cancers14102394 [DOI:10.3390/cancers14102394]
5. Shimoyama M. Diagnostic criteria and classificationof clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group(1984-87). Br J Haematol. Nov 1991;79(3):428-37.doi:10.1111/j.1365-2141.1991.tb08051.x [DOI:10.1111/j.1365-2141.1991.tb08051.x]
6. Katsuya H, Yamanaka T, Ishitsuka K, et al.Prognostic index for acute- and lymphoma-typeadult T-cell leukemia/lymphoma. J Clin Oncol.May 10 2012;30(14):1635-40. doi:10.1200/JCO.2011.38.2101 [DOI:10.1200/JCO.2011.38.2101]
7. Marçais A, Suarez F, Sibon D, Frenzel L, Hermine O,Bazarbachi A. Therapeutic options for adult T-cellleukemia/lymphoma. Current oncology reports.2013;15(5):457-464. [DOI:10.1007/s11912-013-0332-6]
8. Taylor J, Xiao W, Abdel-Wahab O. Diagnosis andclassification of hematologic malignancies on thebasis of genetics. Blood. Jul 27 2017;130(4):410- [DOI:10.1182/blood-2017-02-734541]
9. Kogure Y, Kataoka K. Genetic alterations in adultT-cell leukemia/lymphoma. Cancer Sci. Sep 2017;108(9):1719-1725. doi:10.1111/cas.13303 [DOI:10.1111/cas.13303]
10. Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiplecancers. Nature. Jun 16 2016;534(7607):402-6.doi:10.1038/nature18294 [DOI:10.1038/nature18294]
11. Tsukasaki K, Tanosaki S, DeVos S, et al. Identifyingprogression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. IntJ Cancer. May 10 2004;109(6):875-81. doi:10.1002/ijc.20028 [DOI:10.1002/ijc.20028]
12. Takeuchi M, Miyoshi H, Ohshima K. Tumormicroenvironment of adult T-cell leukemia/lymphoma. J Clin Exp Hematop. 2021;61(4):202-209. doi:10.3960/jslrt.21007 [DOI:10.3960/jslrt.21007]
13. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, ParmianiG, Ferrone S. beta2-Microglobulin mutations,HLA class I antigen loss, and tumor progression inmelanoma. J Clin Invest. Jun 15 1998;101(12):2720-9. doi:10.1172/JCI498 [DOI:10.1172/JCI498]
14. Momburg F, Moller P, Moldenhauer G, HammerlingGJ. Loss of HLA-A,B,C in colorectal carcinomais related to the degree of de-differentiation. JImmunogenet. Apr-Jun 1986;13(2-3):195-9.doi:10.1111/j.1744-313x.1986.tb01101.x [DOI:10.1111/j.1744-313X.1986.tb01101.x]
15. Kataoka K, Nagata Y, Kitanaka A, et al. Integratedmolecular analysis of adult T cell leukemia/lymphoma. Nat Genet. Nov 2015;47(11):1304-15.doi:10.1038/ng.3415 [DOI:10.1038/ng.3415]
16. Ohshima K. Molecular Pathology of Adult T-CellLeukemia/Lymphoma. Oncology. 2015;89 Suppl1:7-15. doi:10.1159/000431058 [DOI:10.1159/000431058]
17. Kogure Y, Kameda T, Koya J, et al. Whole-genomelandscape of adult T-cell leukemia/lymphoma.Blood. Feb 17 2022;139(7):967-982. doi:10.1182/blood.2021013568 [DOI:10.1182/blood.2021013568]
18. Chaib-Mezrag H, Lemacon D, Fontaine H, et al. Taximpairs DNA replication forks and increases DNAbreaks in specific oncogenic genome regions. MolCancer. Sep 4 2014;13:205. doi:10.1186/1476-4598-13-205 [DOI:10.1186/1476-4598-13-205]
19. Moles R, Bai XT, Chaib-Mezrag H, Nicot C. WRN-targeted therapy using inhibitors NSC 19630 and NSC617145 induce apoptosis in HTLV-1-transformedadult T-cell leukemia cells. J Hematol Oncol. Nov 92016;9(1):121. doi:10.1186/s13045-016-0352-4 [DOI:10.1186/s13045-016-0352-4]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
